144226-16-4

Basic information

• Product Name: Carbamic acid, [2-(4-nitrophenyl)ethyl]-, 1,1-dimethylethyl ester
• CAS NO: 144226-16-4
• Molecular Formula: C13H18N2O4
• Molecular Weight: 266.297
• Mol File: 144226-16-4.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [2-(4-nitrophenyl)ethyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [2-(4-nitrophenyl)ethyl]-, 1,1-dimethylethyl ester(144226-16-4)
• EPA Substance Registry System: Carbamic acid, [2-(4-nitrophenyl)ethyl]-, 1,1-dimethylethyl ester(144226-16-4)

Safety Data

• Hazardous Substances Data: 144226-16-4(Hazardous Substances Data)

Upstream product

• 636-98-6 p-nitrobenzene iodide 
• 122234-46-2 2-iodo-1-<(tert-butyloxycarbonyl)amino>ethane 
• 29968-78-3 2-(4-nitrophenyl)ethylamine monohydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 24954-67-4 2-(p-nitrophenyl)ethylamine 
• 26690-80-2 2-(N-tert-butoxycarbonylamino)ethanol 
• 34619-03-9 tert-butyldicarbonate 

Downstream Products

• 94838-59-2 tert-butyl 4-aminophenethylcarbamate 
• 144226-19-7 N-<4-phenethyl>-N^α,N^δ-bis(benzyloxycarbonyl)-N^α-<3-<(benzyloxycarbonyl)amino>propyl>-L-ornithinate 
• 144226-17-5 4--N-<(tert-butyloxy)carbonyl>phenethylamine 
• 91638-05-0 N-<4-(2-Amino-ethyl)-phenyl>-diethanolamin 

Relevant articles and documents

METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION

Provided herein are methods and compositions for targeted protein degradation. In one aspect, a protein degradation chimera is provided, comprising: a first moiety that is capable of binding to a chaperone complex component; a second moiety that is capabl

Synthesis and activity of N-oxalylglycine and its derivatives as Jumonji C-domain-containing histone lysine demethylase inhibitors

N-Oxalylglycine (NOG) derivatives were synthesized, and their inhibitory effect on histone lysine demethylase activity was evaluated. NOG and compound 1 inhibited histone lysine demethylases JMJD2A, 2C and 2D in enzyme assays, and their dimethyl ester prodrugs DMOG and 21 exerted histone lysine methylating activity in cellular assays.

AMINOETHYLAROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR

The present invention relates to aromatic compounds of the formula (I) wherein Ar is phenyl or an aromatic 5-or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical Ra and wherein Ar may also carry 1 or 2 radicals Rb; X is N or CH; E is CR6R7 or NR3;R1 is C1-C4-alkyl, C3-C4-cycloalkyl, C3-C4-cycloalkylmethyl, C3-C4-alkenyl, fluorinated Cl-C4--alkyl, fluorinated C3-C4-cycloalkyl, fluorinated C3-C 4-cycloalkylmethyl, fluorinated C3-C4--alkenyl, formyl or C1-C3-alkylcarbonyl; R1a is H, C1-C4-alkyl, C3-C4-cycloalkyl, C3-C4-cycloalkylmethyl, C3-C4-alkenyl, fluorinated C1--C4-alkyl, fluorinated C3-C4-cycloalkyl, fluorinated C 3-C4-cycloalkylmethyl, fluorinated C3--C 4-alkenyl, or R1a and R2 together are (CH 2)n with n being 2, 3 or 4, or R1a and R 2a together are (CH2)n with n being 2, 3 or 4; R2 and R2a are independently of each other H, C1-C4-alkyl or fluorinated C1-C 4-alkyl or R2a and R2 together are (CH 2)m with m being 1, 2, 3, 4 or 5; R3 is H or C1-C4-alkyl; R6, R7 independently of each other are selected from H, fluorine, C1-C4-alkyl and fluorinated C1-C4-alkyl or together form a moiety (CH2)p with p being 2, 3, 4 or 5; and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.